PRL, prolactin, 5617

N. diseases: 506; N. variants: 3
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0020514
Disease: Hyperprolactinemia
Hyperprolactinemia
0.600 AlteredExpression disease BEFREE Most patients (56.2%) had normal prolactin (PRL) levels and no hyperprolactinemia symptoms (52.5%). 31314867 2020
CUI: C0033375
Disease: Prolactinoma
Prolactinoma
0.600 Biomarker disease BEFREE Women with prolactinomas entering menopause have a higher chance of prolactin normalization of treatment compared with women in their reproductive years. 31686376 2020
CUI: C0033375
Disease: Prolactinoma
Prolactinoma
0.600 AlteredExpression disease BEFREE The patients were divided according to PRL level (normal vs. elevated) and the presence or absence of prolactinoma symptoms. 31314867 2020
CUI: C0033375
Disease: Prolactinoma
Prolactinoma
0.600 AlteredExpression disease BEFREE The association between prolactin level variation and prolactinoma size reduction remains unclear. 31770105 2020
CUI: C0033375
Disease: Prolactinoma
Prolactinoma
0.600 Biomarker disease BEFREE A review of evidence regarding prolactinoma pituitary MRI follow-up; techniques and sequences, recent data on possible gadolinium retention, the role and a review of T2-weighted images in the identification of prolactinomas and frequently encountered clinical scenarios, as well as MRI correlation with prolactin secretion, tumor growth and prediction of response to medical therapy are presented. 31659622 2020
CUI: C0033375
Disease: Prolactinoma
Prolactinoma
0.600 Biomarker disease BEFREE Lactotroph adenomas, also called prolactinomas and prolactin-secreting adenomas, constitute nearly 80% of functioning pituitary tumors and about 30-50% of all adenomas in the clinical practice. 31641970 2020
CUI: C0020514
Disease: Hyperprolactinemia
Hyperprolactinemia
0.600 GeneticVariation disease BEFREE Prevalence of macroprolactinemia was 21.57% (22/102) in hyperprolactinemia (prolactin >100 ng/ml). 30269265 2019
CUI: C0020514
Disease: Hyperprolactinemia
Hyperprolactinemia
0.600 AlteredExpression disease BEFREE The total cholesterol (baseline, 236.1 ± 47.6 mg/dl; endpoint [week 12], 209.9 ± 28.0 mg/dl; p = 0.005) and prolactin levels (baseline, 80.0 ± 85.2 ng/ml; endpoint [week 12], 63.2 ± 88.9 ng/ml; p = 0.003) were also significantly improved in patients with hypercholesterolemia or hyperprolactinemia. 31352709 2019
CUI: C0020514
Disease: Hyperprolactinemia
Hyperprolactinemia
0.600 AlteredExpression disease BEFREE The study population consisted of 3 age-, weight-, and lipid-matched groups of young women: 19 women with untreated hyperprolactinemia (group A), 20 normoprolactinemic women receiving bromocriptine treatment (because of previous hyperprolactinemia) (group B), and 20 untreated women with prolactin levels within the reference range (group C). 30129670 2019
CUI: C0020514
Disease: Hyperprolactinemia
Hyperprolactinemia
0.600 AlteredExpression disease BEFREE The study population included 11 men with isolated macroprolactinemia, 14 subjects with monomeric hyperprolactinemia and 14 men with prolactin levels within the reference range. 31185509 2019
CUI: C0020514
Disease: Hyperprolactinemia
Hyperprolactinemia
0.600 AlteredExpression disease BEFREE Sex and age were significantly associated with PRL levels in patients treated with LAI antipsychotics, with younger women presenting higher rates of HPRL than men. 30848967 2019
CUI: C0020514
Disease: Hyperprolactinemia
Hyperprolactinemia
0.600 AlteredExpression disease BEFREE Hyperprolactinemia was found to be present in Case 2, whereas Case 1 (a 49-year-old woman) had "normal" serum prolactin levels for premenopausal and prolactin levels slightly above the maximum levels for postmenopausal women. 31417404 2019
CUI: C0020514
Disease: Hyperprolactinemia
Hyperprolactinemia
0.600 Biomarker disease BEFREE Molecular studies are shedding light on the pathophysiology of hyperprolactinemia and the effects of excess prolactin production on the reproductive system. 31045655 2019
CUI: C0020514
Disease: Hyperprolactinemia
Hyperprolactinemia
0.600 AlteredExpression disease BEFREE Hyperprolactinemia was suspected because of adrenal deficiency that was directly or indirectly associated with increased prolactin levels. 30958070 2019
CUI: C0020514
Disease: Hyperprolactinemia
Hyperprolactinemia
0.600 Biomarker disease BEFREE In this review, we provide an update on the diagnostic and management approaches for the patient with hyperprolactinaemia and on the current data looking at the impact of high prolactin on metabolism, cardiovascular and immune systems. 31847209 2019
CUI: C0020514
Disease: Hyperprolactinemia
Hyperprolactinemia
0.600 Biomarker disease BEFREE The association of hyperprolactinemia with the severity of the clinical picture has also been demonstrated, higher prolactin values indicating a stronger clinical picture, which calls into question the protective role of prolactin in psychotic disorders. 31158115 2019
CUI: C0020514
Disease: Hyperprolactinemia
Hyperprolactinemia
0.600 Biomarker disease BEFREE Prl replacement in Bromo-treated mice normalized serum Prl concentration without inducing hyperprolactinemia. 30462197 2019
CUI: C0020514
Disease: Hyperprolactinemia
Hyperprolactinemia
0.600 Biomarker disease BEFREE The Impact of Ethinyl Estradiol on Metformin Action on Prolactin Levels in Women with Hyperprolactinemia. 31234219 2019
CUI: C0020514
Disease: Hyperprolactinemia
Hyperprolactinemia
0.600 Biomarker disease BEFREE Psychological effects of dopamine agonist treatment in patients with hyperprolactinemia and prolactin-secreting adenomas. 30400048 2019
CUI: C0020514
Disease: Hyperprolactinemia
Hyperprolactinemia
0.600 Biomarker disease BEFREE PRL values >250 ng/mL are highly suggestive of prolactinomas and virtually exclude nonfunctioning pituitary adenomas (NFPAs) and other sellar masses as the etiology of hyperprolactinemia. 30889571 2019
CUI: C0020514
Disease: Hyperprolactinemia
Hyperprolactinemia
0.600 AlteredExpression disease BEFREE The impact of fenofibrate on total cholesterol, LDL cholesterol, HDL cholesterol and triglyceride levels, as well as on uric acid, hsCRP, homocysteine, and fibrinogen was less pronounced in women with untreated hyperprolactinemia than in women with bromocriptine-treated hyperprolactinemia and drug-naïve women with normal prolactin levels. 30469130 2019
CUI: C0033375
Disease: Prolactinoma
Prolactinoma
0.600 AlteredExpression disease BEFREE A strong correlation was found between prolactinoma volume and serum prolactin level (r = 0.831, p < 0.001). 31200381 2019
CUI: C0033375
Disease: Prolactinoma
Prolactinoma
0.600 GeneticVariation disease BEFREE We hypothesize that the alteration of PRL actions in lactotrope homeostasis due to the dysregulation of any of the mechanisms of actions described above may contribute to the pathogenesis of prolactinomas. 30376668 2019
CUI: C0033375
Disease: Prolactinoma
Prolactinoma
0.600 Biomarker disease BEFREE Herein, we survey the role of prolactin and prolactinomas in pregnancy while also outlining the therapeutic approach to prolactinoma during pregnancy. 30341577 2019
CUI: C0033375
Disease: Prolactinoma
Prolactinoma
0.600 Biomarker disease BEFREE The objective of this systematic review was to systematically assess the effect of reducing prolactin with dopamine agonist on established cardiovascular risk factors in patients with prolactinomas. 31518995 2019